Exercise of Options and Total Voting Rights

Destiny Pharma PLC

19 March 2024

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Exercise of Options and Total Voting Rights

Brighton, United Kingdom - 19 March 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, announces that it has issued and allotted 40,000 new ordinary shares of 1 pence each in the capital of the Company (the "New Ordinary Shares") following an exercise of share options by a former employee.

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 25 March 2024 ("Admission").

Following Admission, the Company will have a total of 95,311,863 Ordinary Shares in issue. Shareholders may use this figure of 95,311,863 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- END -

For further information, please contact:

Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

FTI Consulting

Ben Atwell / Simon Conway

[phone]

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

For further information on the company, please visit www.destinypharma.com

 

END